近日，云知声 (09678.HK) 创始人兼首席执行官黄伟在与凤凰网财经《发现新势力》对话时，谈及能否 用 AI 医疗能力满足用户健康搜索需求的问题，他表示该需求是明确的，云知声未来一定会布局相关业 务，但因医疗的严肃性，会先与顶尖公立三甲医院合作打磨模型能力，达到高水准后再向 C 端用户提 供相关服务。 黄伟：人最核心的需求无非是快乐和健康，用户的健康搜索需求印证了健康需求的重要性，这个事我们 一定会做。但医疗是非常严肃的领域，我们十几年前做医疗就坚持做严肃医疗，即便它门槛高、短期商 业回报低。中美医疗资源分布不同，中国最优质的医疗资源和医学知识财富都集中在公立三甲医院，各 医院还有专科特色。所以云知声会先和这些顶尖三甲医院合作，了解医生需求、提升模型能力，等模型 能力达到非常高的水平后，我们才会负责任地为 C 端用户提供相关健康服务。 凤凰网财经《发现新势力》：PC 时代大家有大量医疗疾病类的搜索需求，这是很大的商业需求，你们 是否想过用 AI 医疗能力来满足这一需求？ ...

Core Insights - The core objective of Yunzhisheng's AI medical layout is to promote equity in healthcare, addressing issues such as difficulty in accessing medical services, high costs, and uneven distribution of medical resources [1][2]. Group 1: Company Vision and Goals - The company aims to leverage AI medical capabilities to serve under-resourced areas, particularly in central and western regions of China, and to provide convenience for elderly individuals at home [2]. - The founder emphasizes the importance of creating "human-centered" AI that serves humanity and adds value, rather than replacing or controlling humans [2]. Group 2: Industry Challenges - The conversation highlights prevalent challenges in the healthcare industry, including the difficulty of obtaining quality medical care locally, which often necessitates travel to major cities like Beijing and Shanghai for treatment [2].

自动播放 出品 | 凤凰网财经《发现新势力》 黄伟：人最核心的需求无非是快乐和健康，用户的健康搜索需求印证了健康需求的重要性，这个事我们 一定会做。但医疗是非常严肃的领域，我们十几年前做医疗就坚持做严肃医疗，即便它门槛高、短期商 业回报低。中美医疗资源分布不同，中国最优质的医疗资源和医学知识财富都集中在公立三甲医院，各 医院还有专科特色。所以云知声会先和这些顶尖三甲医院合作，了解医生需求、提升模型能力，等模型 能力达到非常高的水平后，我们才会负责任地为 C 端用户提供相关健康服务。 本文来源为凤凰网财经《发现新势力》对话黄伟，完整视频内容在凤凰新闻客户端上线。 近日，云知声 (09678.HK) 创始人兼首席执行官黄伟在与凤凰网财经《发现新势力》对话时，谈及能否 用 AI 医疗能力满足用户健康搜索需求的问题，他表示该需求是明确的，云知声未来一定会布局相关业 务，但因医疗的严肃性，会先与顶尖公立三甲医院合作打磨模型能力，达到高水准后再向 C 端用户提 供相关服务。 （以下内容节选自《发现新势力》对话黄伟，对话实录有删减） 凤凰网财经《发现新势力》：PC 时代大家有大量医疗疾病类的搜索需求，这是很大的商业需求，你 ...

板块表现： 证券研究报告 医药生物 行业定期报告 hyzqdatemark 2026 年 02 月 09 日 刘闯 SAC：S1350524030002 liuchuang@huayuanstock.com 分子胶：撬动"不可成药"靶点的创新药新范式 投资评级： 看好（维持） ——医药行业周报（26/2/2-26/2/6） 投资要点： 请务必仔细阅读正文之后的评级说明和重要声明 证券分析师 联系人 本周医药市场表现分析：2 月 2 日至 2 月 6 日，医药指数上涨 0.14%，相对沪深 300 指数超 额收益为 1.47%。上周市场风格有所变化，白酒等底部消费类资产表现较好，医药行业中的 医疗服务、中药亦有表现。另外，经历短期波动消化后，创新药板块已显现企稳回暖迹象。 我们建议精选基本面强劲、前期调整充分的创新药个股，看好未来股价有望走出新高度，同 时建议积极关注医疗新科技等板块，以及 26 年困境反转的底部个股。1）创新药建议关注，A 股）恒瑞医药、信立泰、泽璟制药、热景生物、科伦药业、上海谊众、康弘药业、华纳药厂、 前沿生物、福元医药、苑东生物、昂利康；港股）中国生物制药、三生制药、信达生物、康 方生物 ...

Core Insights - The report emphasizes the strategic importance of the raw material pharmaceutical sector, highlighting price recovery and new business increments as key drivers for growth in the industry [3][4][9] - The pharmaceutical sector is currently viewed as being at a bottoming phase, with opportunities arising from innovative drug developments and the integration of new technologies such as AI and brain-computer interfaces [4][6][8] Market Performance - In January 2026, the pharmaceutical and biotechnology sector saw a 3.1% increase, outperforming the CSI 300 index, which rose by 1.7%, resulting in a 1.49 percentage point lead [3][11] - Specific segments within the pharmaceutical industry, such as medical services and medical devices, experienced significant gains, with increases of 8.82% and 5.28% respectively [3][11] Investment Strategy - The report suggests focusing on the raw material pharmaceutical sector, which is expected to benefit from price recovery and the introduction of new business lines, particularly in small nucleic acids, peptides, and ADCs [4][5][9] - Companies with strong technical capabilities and production capacity, such as Lianhua Technology and Aorite, are highlighted as key players to watch [5] Innovation and New Opportunities - The report identifies several innovative drug sectors, including small nucleic acids and ADCs, as having significant growth potential, driven by clinical advancements and market demand [5][9] - The report also notes that the ADC market is expected to grow significantly, with a projected market size of $11 billion by 2030, indicating a strong opportunity for companies involved in this space [9] Recommendations - Key stocks recommended for investment include WuXi Biologics, Tigermed, and Kanghong Pharmaceutical, which have shown strong performance and are expected to continue to do so [10] - The report also highlights the importance of monitoring developments in AI and brain-computer interface technologies, which are anticipated to drive future growth in the pharmaceutical sector [8]

Summary of Key Points from Conference Call Records Industry Overview - **Surgical Robot Industry**: The Chinese surgical robot industry is experiencing rapid development, supported by national policies and capital investment. Key technological advancements include remote operation, miniaturization, and AI assistance. The market for laparoscopic surgical robots is projected to reach 40.543 billion yuan by 2033, with a CAGR of 28.7% from 2024 to 2033 [doc id='21'][doc id='19']. Core Insights and Arguments - **Investment Opportunities in Innovative Drugs and CRO**: Despite past challenges, investment activity in innovative drugs and Contract Research Organizations (CRO) is expected to rise significantly. Business development (BD) amounts are anticipated to reach new highs, with companies like Rongchuang and Shiyao achieving attractive upfront payment ratios [doc id='3'][doc id='4']. - **Medical Device Sector Recovery**: The medical device sector is nearing the end of its inventory destocking phase, with performance expected to improve gradually in 2026. The resumption of procurement rhythms and an increase in bidding volumes are noted trends [doc id='5']. - **IVD Sector Outlook**: The In Vitro Diagnostics (IVD) sector is expected to face pressure in 2025, but conditions are projected to improve in 2026 as pricing pressures ease and policies are fully implemented [doc id='8'][doc id='9']. - **Traditional Chinese Medicine (TCM) Recovery**: The TCM sector is anticipated to bottom out in Q2 2026, with a potential recovery in 2027 driven by policy support and demand resurgence [doc id='10']. Additional Important Insights - **AI Medical and Brain-Computer Interface Technologies**: AI in healthcare is crucial for enhancing productivity, though its commercialization path remains uncertain. The brain-computer interface sector shows promise but also faces commercialization challenges [doc id='6']. - **CRO Sector Performance**: The CRO sector is showing strong order and operational performance, with companies like Kanglong Huacheng making significant progress in commercial production [doc id='11']. - **Market Dynamics for Surgical Robots**: The market for surgical robots is transitioning from an introduction phase to a growth phase, with increasing sales but slower revenue growth, indicating a structural transformation [doc id='19']. - **Regulatory Developments**: The National Medical Insurance Administration's guidelines are expected to accelerate the clinical application of surgical robots by establishing legitimate billing items [doc id='19']. Company-Specific Highlights - **Shiyao Group and AstraZeneca Collaboration**: The collaboration in the weight loss and metabolism field has set historical highs for upfront payments and total package amounts, although the overall sentiment in the sector remains subdued [doc id='7']. - **Kanglong Huacheng's Growth**: The company is expected to see a significant increase in order retention rates with the launch of its Shaoxing Phase II project, enhancing its competitive position in the CRO market [doc id='12']. - **Emerging Companies**: Companies like Tianyu and Starly are projected to enter performance inflection points this year, with significant growth potential in the raw material pharmaceutical sector [doc id='13'][doc id='14']. This summary encapsulates the key points from the conference call records, highlighting the current state and future outlook of various sectors within the healthcare and pharmaceutical industries in China.

Group 1: Machinery Manufacturing Industry - The domestic demand for construction machinery has fully recovered, and overseas growth has accelerated, indicating a positive long-term outlook for the industry [2] - Recommended companies include SANY Heavy Industry, XCMG, Zoomlion (A/H), Liugong, Shantui, and China Longgong (H), along with component manufacturers like Hengli Hydraulic [2] - The smart logistics sector is expected to open up growth opportunities in the forklift industry, with recommendations for Anhui Heli and Hangcha Group, and a suggestion to pay attention to Zhongli and Nuoli [2] Group 2: Dairy Industry - Junlebao, starting from yogurt, launched its first infant formula in 2014, and has since developed strong single product capabilities, with "Jianchun" becoming the top low-temperature yogurt brand in China since 2022 [3] - The high-end fresh milk brand "Yuexianhuo" is projected to achieve revenue of 1.88 billion yuan in 2024, establishing itself as a leading brand in the high-end fresh milk segment [3] - For the first three quarters of 2025, "Yuexianhuo" has generated revenue of 1.84 billion yuan, reflecting a year-on-year growth of 37.6% [3] Group 3: AI in Healthcare - Domestic and international healthcare companies are increasingly investing in AI products and services across various segments, including health management, precision medicine, and AI-driven clinical trials [4] - The report emphasizes the transition of AI in healthcare from technical validation to commercial realization, driven by the dual forces of cost control in healthcare and technological advancements [4] - The core competitive advantage in the future will depend on possessing exclusive, high-quality private data and the ability to continuously iterate data through business scenarios [4]

Group 1: Company Overview and AI Medical Layout - Guangzhou Wanfu Biological Technology Co., Ltd. has been investing in AI medical since 2018, aiming to become a leading enterprise in the domestic AI medical field through a "merger + hospital end + consumer end" strategy [2][4] - The company’s investment in Saiweisen Medical Technology led to the first domestic Class III medical device registration for cervical cancer cell digital pathology software in February 2025 [2][3] - Wanfu has developed the "Wanfu Smart Inspection" AI platform for hospitals, which has been implemented in various medical scenarios [3][4] Group 2: Investment and Collaboration - The company collaborates with Saiweisen, Shengqiang, and Yizhun Intelligent to enhance diagnostic capabilities through software and hardware integration [4][5] - The partnership aims to leverage each company's strengths in imaging, pathology, and laboratory testing to capture opportunities in AI applications [4][5] Group 3: Product Development and Market Position - Saiweisen has received the first Class III certification for AI-assisted diagnosis in gynecology, with ongoing clinical trials for non-gynecological applications [5][6] - Shengqiang Technology has developed a comprehensive digital pathology solution, covering approximately 2,000 hospitals domestically and 12 overseas regions [7][8] - Yizhun Intelligent holds 15 Class II and 6 Class III certifications, with a focus on ultrasound AI technology, which is more complex than radiology AI [9][10] Group 4: Market Trends and Future Outlook - The introduction of new policies is expected to significantly increase the volume of digital slices in the pathology market, creating substantial market capacity [8][9] - The AI medical sector is projected to grow rapidly, with a focus on enhancing brand influence and operational efficiency through innovative AI applications [10][11] - The company anticipates a recovery in domestic business in 2026, supported by overseas growth driven by various platforms [12][13]

Investment Rating - The report maintains a "Recommended" investment rating for the computer industry [2][6]. Core Insights - The AI medical sector is experiencing rapid development, with significant commercial opportunities emerging. Major players like NVIDIA and Eli Lilly are investing heavily in AI drug development, while domestic companies like Ant Group are promoting AI health management products [5][13][14]. - Alibaba's Qianwen app has transitioned into the "AI service era," integrating over 400 AI service functions and achieving over 100 million monthly active users, indicating strong user engagement and ecosystem integration [15][17]. - The report highlights the importance of AI infrastructure development in China, emphasizing the need for a self-sufficient and efficient computing foundation to support the growing demand for AI applications [16]. Summary by Sections AI Empowerment in Healthcare - The report notes that AI is reaching a commercialization inflection point in healthcare, with significant investments and partnerships forming to accelerate AI drug development and health management solutions [5][13][14]. - Key areas of growth include AI drug development, AI-assisted medical imaging, and personal health management, which are expected to see increased investment and demand [14]. Development of AI Ecosystem - Domestic tech giants are leveraging their vast user bases and data resources to build comprehensive AI ecosystems, enhancing user experience and operational efficiency [15][16]. - The integration of AI services within existing platforms is seen as a critical factor for rapid deployment and market penetration [15]. Investment Recommendations - The report suggests focusing on AI computing companies such as Cambricon (688256.SH), Haiguang Information (688041.SH), Inspur Information (000977.SZ), and Zhongke Shuguang (603019.SH) [6][17]. - It also recommends monitoring vertical AI application companies like Kingsoft Office (688111.SH), Dingjie Zhizhi (300378.SZ), and Han's Information (300170.SZ) for potential investment opportunities [6][17].

Investment Rating - The report maintains a "Recommended" investment rating for the computer industry [2][6]. Core Insights - The AI medical sector is experiencing rapid development, with significant commercial opportunities emerging. Major players like NVIDIA and Eli Lilly are investing heavily in AI drug development, while domestic companies like Ant Group are promoting AI health management products [5][13][14]. - Alibaba's Qianwen app has transitioned into the "AI service era," integrating over 400 AI service functions and achieving over 100 million monthly active users, showcasing the potential for AI applications in enhancing user experience and operational efficiency [15][17]. - The report emphasizes the importance of building a self-sufficient and efficient computing infrastructure in response to increasing global competition and the exponential growth of AI application demands [16]. Summary by Sections AI Empowerment in Healthcare - The AI healthcare sector is at a commercial inflection point, with significant investments from both domestic and international companies. Key areas of growth include AI drug development, medical imaging analysis, and personal health management, which are expected to see increased investment value as clinical validation and regulatory frameworks improve [5][14]. Development of AI Ecosystem - Domestic tech giants are rapidly advancing their AI ecosystems, leveraging their large user bases and data resources. This integration is expected to enhance service delivery and operational efficiency across various sectors [15][16]. Market Performance - The computer sector index rose by 3.82% from January 12 to January 16, 2026, indicating positive market sentiment [8]. Key Companies and Investment Recommendations - The report highlights several companies for investment consideration, including: - AI Computing: Cambrian (688256.SH), Haiguang Information (688041.SH), Inspur Information (000977.SZ), and Zhongke Shuguang (603019.SH) [6][17]. - Vertical AI Applications: Kingsoft Office (688111.SH), Dingjie Zhizhi (300378.SZ), Hand Information (300170.SZ), and others [6][17].